vs

Side-by-side financial comparison of Kosmos Energy Ltd. (KOS) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.

Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $294.6M, roughly 1.7× Kosmos Energy Ltd.). On growth, Pediatrix Medical Group, Inc. posted the faster year-over-year revenue change (-1.7% vs -25.9%). Over the past eight quarters, Pediatrix Medical Group, Inc.'s revenue compounded faster (-0.1% CAGR vs -16.5%).

Kosmos Energy is an American upstream oil company founded and based in Dallas, Texas. While previously incorporated in Bermuda, Kosmos has reincorporated in Delaware. The company holds production and development operations offshore Ghana, Equatorial Guinea, and Gulf of Mexico, while holding a development project offshore Mauritania and Senegal, and exploration licenses offshore Namibia, São Tomé and Príncipe and Suriname. It was previously involved in exploration offshore Morocco and Western ...

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

KOS vs MD — Head-to-Head

Bigger by revenue
MD
MD
1.7× larger
MD
$493.8M
$294.6M
KOS
Growing faster (revenue YoY)
MD
MD
+24.2% gap
MD
-1.7%
-25.9%
KOS
Faster 2-yr revenue CAGR
MD
MD
Annualised
MD
-0.1%
-16.5%
KOS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KOS
KOS
MD
MD
Revenue
$294.6M
$493.8M
Net Profit
$33.7M
Gross Margin
Operating Margin
-125.7%
9.9%
Net Margin
6.8%
Revenue YoY
-25.9%
-1.7%
Net Profit YoY
10.5%
EPS (diluted)
$-0.80
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KOS
KOS
MD
MD
Q4 25
$294.6M
$493.8M
Q3 25
$311.0M
$492.9M
Q2 25
$392.6M
$468.8M
Q1 25
$290.1M
$458.4M
Q4 24
$397.6M
$502.4M
Q3 24
$407.8M
$511.2M
Q2 24
$447.8M
$504.3M
Q1 24
$422.3M
$495.1M
Net Profit
KOS
KOS
MD
MD
Q4 25
$33.7M
Q3 25
$-124.3M
$71.7M
Q2 25
$-87.7M
$39.3M
Q1 25
$-110.6M
$20.7M
Q4 24
$30.5M
Q3 24
$45.0M
$19.4M
Q2 24
$59.8M
$-153.0M
Q1 24
$91.7M
$4.0M
Operating Margin
KOS
KOS
MD
MD
Q4 25
-125.7%
9.9%
Q3 25
-34.2%
13.8%
Q2 25
-16.2%
12.8%
Q1 25
-32.4%
7.0%
Q4 24
-8.5%
7.8%
Q3 24
26.1%
6.6%
Q2 24
30.2%
-31.3%
Q1 24
33.6%
3.2%
Net Margin
KOS
KOS
MD
MD
Q4 25
6.8%
Q3 25
-40.0%
14.5%
Q2 25
-22.3%
8.4%
Q1 25
-38.1%
4.5%
Q4 24
6.1%
Q3 24
11.0%
3.8%
Q2 24
13.3%
-30.3%
Q1 24
21.7%
0.8%
EPS (diluted)
KOS
KOS
MD
MD
Q4 25
$-0.80
$0.40
Q3 25
$-0.26
$0.84
Q2 25
$-0.18
$0.46
Q1 25
$-0.23
$0.24
Q4 24
$0.00
$0.37
Q3 24
$0.09
$0.23
Q2 24
$0.12
$-1.84
Q1 24
$0.19
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KOS
KOS
MD
MD
Cash + ST InvestmentsLiquidity on hand
$91.5M
$375.2M
Total DebtLower is stronger
$3.1B
$570.5M
Stockholders' EquityBook value
$528.6M
$865.9M
Total Assets
$4.7B
$2.2B
Debt / EquityLower = less leverage
5.78×
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KOS
KOS
MD
MD
Q4 25
$91.5M
$375.2M
Q3 25
$64.0M
$340.1M
Q2 25
$51.7M
$224.7M
Q1 25
$49.8M
$99.0M
Q4 24
$85.0M
$229.9M
Q3 24
$51.6M
$103.8M
Q2 24
$173.8M
$19.4M
Q1 24
$254.3M
$8.0M
Total Debt
KOS
KOS
MD
MD
Q4 25
$3.1B
$570.5M
Q3 25
$3.0B
$577.2M
Q2 25
$2.9B
$583.9M
Q1 25
$590.5M
Q4 24
$2.7B
$597.1M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
KOS
KOS
MD
MD
Q4 25
$528.6M
$865.9M
Q3 25
$898.8M
$890.7M
Q2 25
$1.0B
$833.8M
Q1 25
$1.1B
$789.2M
Q4 24
$1.2B
$764.9M
Q3 24
$1.2B
$732.5M
Q2 24
$1.1B
$706.5M
Q1 24
$1.1B
$856.2M
Total Assets
KOS
KOS
MD
MD
Q4 25
$4.7B
$2.2B
Q3 25
$5.1B
$2.2B
Q2 25
$5.2B
$2.1B
Q1 25
$5.3B
$2.0B
Q4 24
$5.3B
$2.2B
Q3 24
$5.5B
$2.1B
Q2 24
$5.4B
$2.0B
Q1 24
$5.4B
$2.2B
Debt / Equity
KOS
KOS
MD
MD
Q4 25
5.78×
0.66×
Q3 25
3.31×
0.65×
Q2 25
2.80×
0.70×
Q1 25
0.75×
Q4 24
2.29×
0.78×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KOS
KOS
MD
MD
Operating Cash FlowLast quarter
$35.3M
$114.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.39×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KOS
KOS
MD
MD
Q4 25
$35.3M
$114.1M
Q3 25
$-27.6M
$137.3M
Q2 25
$127.2M
$137.2M
Q1 25
$-888.0K
$-117.5M
Q4 24
$175.7M
$133.0M
Q3 24
$6.3M
$91.8M
Q2 24
$223.7M
$107.0M
Q1 24
$272.6M
$-125.2M
Cash Conversion
KOS
KOS
MD
MD
Q4 25
3.39×
Q3 25
1.91×
Q2 25
3.49×
Q1 25
-5.66×
Q4 24
4.36×
Q3 24
0.14×
4.72×
Q2 24
3.74×
Q1 24
2.97×
-31.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KOS
KOS

Ghana Segment$134.6M46%
Gulf Of America$80.7M27%
Mauritania And Senegal$54.9M19%
Equatorial Guinea Segment$24.3M8%

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

Related Comparisons